New Gene Therapy May Prove Useful Against Cancer Patients' Fungal Infections
the Cancer Therapy Advisor take:
The Sleeping Beauty gene transfer system “awakens” transposon, which are DNA sequences that researchers find useful for altering DNA inside human cells. Sleeping Beauty exploits the transposon so that it can relocate genetic material with a “cut and paste” approach.
According to a study published in Proceedings of the National Academy of Sciences, researchers fought infections by invasive Aspergillus fungus by modifying T cells with the Sleeping Beauty gene transfer system. Research leader Laurence Cooper, MD, PhD, and researchers at The University of Texas MD Anderson Cancer Center used Sleeping Beauty to make T cells express chimeric antigen receptors (CARs), which caused the T cells to target sugar molecules in Aspergillus cell walls. This approach may prove useful for immunosuppressed patients, such as patients with hematopoietic stem cell transplants, which treat blood or bone marrow cancers.
Dimitrios Kontoyiannis, MD, ScD, said although antifungal therapies are available, the drugs’ effectiveness is compromised due to the patient’s weakened immune system from hematopoietic stem cell transplants as well as emerging resistance to antifungals. Cooper said that his research team studied their new gene therapy against fungus due to CARs’ successful treatment of patients with B-cell malignancies.
Redirecting T-cell specificity opens up the potential for more investigations of its effects on other pathogens and malignancies.
New Gene Therapy May Prove Useful Against Cancer Patients’ Fungal Infections
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma